发布求助
文献互助 智能选刊 最新文献

Cancer clinical trials最新文献

筛选
英文 中文
Bone, muscle, soft tissue workshop. 骨、肌肉、软组织车间。
Cancer clinical trials Pub Date : 1981-01-01
L W Brady, H Suit
{"title":"Bone, muscle, soft tissue workshop.","authors":"L W Brady, H Suit","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":75672,"journal":{"name":"Cancer clinical trials","volume":"4 Suppl ","pages":"9-13"},"PeriodicalIF":0.0,"publicationDate":"1981-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"18319557","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A system for determining the pharmacology of indirect radiation sensitizer drugs on multicellular spheroids. 一种测定多细胞球体间接辐射增敏药物药理学的系统。
Cancer clinical trials Pub Date : 1981-01-01
N Kaufman, H I Bicher, F W Hetzel, M Brown
{"title":"A system for determining the pharmacology of indirect radiation sensitizer drugs on multicellular spheroids.","authors":"N Kaufman,&nbsp;H I Bicher,&nbsp;F W Hetzel,&nbsp;M Brown","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>We have characterized some of the physiology of multicellular spheroids of different sizes grown from Chinese hamster lung fibroblast (V79) cells. Among the parameters studied were oxygen tension distributions within the spheroid. This was achieved using ultramicroelectrodes with tip diameters of 1-5 mu and a perfusion system whereby environmental conditions such as flow, temperature, and chemical makeup of the milieu could be measured and controlled. Plateau pO2 values of less than 10 mm Hg were consistently obtained from spheroids under various conditions. We were able to modify these distributions by use of indirect radiation sensitizer drugs such as mechlorethamine HCl (mustargen) at nontoxic doses. We have also made determinations of the inhibitory capacities of several other drugs on the respiration rate of constituent cells of multicellular spheroids in single-cell suspensions. We have concluded that there are indeed hypoxic cells in spheroids whose radioresistance may be modified by essentially nontoxic levels of indirect radiosensitizer drugs and that the system described shows great promise for screening agents which may modify radiation response.</p>","PeriodicalId":75672,"journal":{"name":"Cancer clinical trials","volume":"4 2","pages":"199-204"},"PeriodicalIF":0.0,"publicationDate":"1981-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"18262298","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Flow cytometric analysis of bone marrow in a patient with resistant neuroblastoma. 1例耐药神经母细胞瘤患者骨髓流式细胞术分析。
Cancer clinical trials Pub Date : 1981-01-01
L Helson, F Traganos, D Miller
{"title":"Flow cytometric analysis of bone marrow in a patient with resistant neuroblastoma.","authors":"L Helson,&nbsp;F Traganos,&nbsp;D Miller","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Using flow cytometric analysis, we followed changes in a patient's bone marrow which was infiltrated with cells resistant to chemotherapy. Samples taken prior to, during, and after treatment with dianhydrogalactitol (2 days), cytosine arabinoside and hydroxyurea (2 days), and Adriamycin (2 days) contained an aneuploid population of cells which exhibited changes in ploidy, viability, and distribution in cell cycle compartment. The restricted changes in cell ploidy and viability of tumor cells encountered as well as limited increases in S phase on day 4 and G2 phase on day 6 with a rebound on day 9 of G1 phase cells suggest the tumor to be sensitive to dianhydrogalactitol but not to the other agents used.</p>","PeriodicalId":75672,"journal":{"name":"Cancer clinical trials","volume":"4 4","pages":"415-21"},"PeriodicalIF":0.0,"publicationDate":"1981-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"18330106","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Phase I study of aziridinylbenzoquinone (NSC 182986). aziridinylbenzoquinone (NSC 182986)的一期研究。
Cancer clinical trials Pub Date : 1981-01-01
A Y Bedikian, G P Bodey, M A Burgess, E J Freireich
{"title":"Phase I study of aziridinylbenzoquinone (NSC 182986).","authors":"A Y Bedikian,&nbsp;G P Bodey,&nbsp;M A Burgess,&nbsp;E J Freireich","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>A phase I clinical study of aziridinylbenzoquinone (AZQ) was conducted in 33 patients with various types of advanced solid tumors to evaluate its toxicity and efficacy. The initial dose of 0.5 mg/m2/day X 5 days repeated at 3-week intervals was progressively increased to a maximum dose of 12.0 mg/m2/day. Thrombocytopenia was the dose-limiting toxic effect; it was delayed, cumulative, and occurred more often in patients with extensive prior chemotherapy and radiotherapy. Anemia was common and severe at higher doses, while nausea and vomiting were observed only in some patients and usually were mild. Objective tumor regressions were observed in 3 of 17 patients who received biologically active doses of AZQ, i.e., 6 mg/m2/day or higher. Minor responses were seen in two of three patients with malignant melanoma and in a patient with adenocarcinoma of unknown primary. The recommended starting dose of AZQ for good-risk patients is 8.0 mg/m2/day X 5 days for phase II studies.</p>","PeriodicalId":75672,"journal":{"name":"Cancer clinical trials","volume":"4 4","pages":"459-63"},"PeriodicalIF":0.0,"publicationDate":"1981-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"18330110","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
MER immunotherapy and combination chemotherapy for advanced, recurrent Hodgkin's disease. Cancer and Leukemia Group B study. 晚期复发何杰金氏病的MER免疫治疗和联合化疗。癌症和白血病B组研究。
Cancer clinical trials Pub Date : 1981-01-01
V Vinciguerra, M Coleman, T F Pajak, S Rafla, L Stutzman, G Gomez, M Weil, K Brunner, J Cuttner, N Nissen, B Leventhal, A Gottlieb
{"title":"MER immunotherapy and combination chemotherapy for advanced, recurrent Hodgkin's disease. Cancer and Leukemia Group B study.","authors":"V Vinciguerra,&nbsp;M Coleman,&nbsp;T F Pajak,&nbsp;S Rafla,&nbsp;L Stutzman,&nbsp;G Gomez,&nbsp;M Weil,&nbsp;K Brunner,&nbsp;J Cuttner,&nbsp;N Nissen,&nbsp;B Leventhal,&nbsp;A Gottlieb","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The effects of chemotherapy and chemoimmunotherapy in previously treated advanced Hodgkin's disease were evaluated in a randomized study of 167 patients by CALGB. Combination chemotherapy consisted of treatment with one of three regimens with further randomization of MER (methanol extraction residue BCG) immunotherapy or no MER during chemotherapy. CVPP (CCNU, vinblastine, procarbazine, prednisone) was compared to a new combination, BAVS (bleomycin, Adriamycin, vincristine, streptozotocin), and to a third regimen consisting of alternating cycles of CVPP and BAVS. At the current analysis there is no significant difference in complete responses among the chemotherapy regimens. MER did not improve complete response frequency and was associated with significantly poorer survival for patients previously treated with chemotherapy. There was also no benefit with MER for patients with at least one pretreatment positive skin test. Because of the documented lack of therapeutic benefit and the morbidity of painful ulcers, MER treatment has been discontinued.</p>","PeriodicalId":75672,"journal":{"name":"Cancer clinical trials","volume":"4 2","pages":"99-105"},"PeriodicalIF":0.0,"publicationDate":"1981-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"18067113","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The pathologic effects of fractionated fast neutrons or photons on canine liver. 分异快中子或光子对犬肝脏的病理影响。
Cancer clinical trials Pub Date : 1981-01-01
B C Zook, E W Bradley, G W Casarett, R A Hitzelberg, C C Rogers
{"title":"The pathologic effects of fractionated fast neutrons or photons on canine liver.","authors":"B C Zook,&nbsp;E W Bradley,&nbsp;G W Casarett,&nbsp;R A Hitzelberg,&nbsp;C C Rogers","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Thirty-nine adult male purebred beagles received either fast neutron or photon irradiation to the right thorax to determine the effects on pulmonary tissue. The right half of the liver was included in the field of radiation. Twenty-four dogs (six/group) received fast neutrons with a mean energy of 15 MeV to total doses of 1000, 1500, 2250, or 3375 rads in four fractions per week for 6 weeks. Fifteen dogs received 3000, 4500, or 6750 total rads of photons (five dogs/group) in an identical fractionation pattern. All neutron-irradiated dogs receiving 3375 and 2250 rads and one receiving 1500 rads developed clinical signs, hepatic enzyme, and bilirubin elevations, and the dogs died or were euthanized in extremis on postirradiation day 47-291. Signs of liver injury, other than enzyme changes, have not developed to date (1200-1300 days) in the remaining dogs, except in one 6750-rad photon dog that died of hepatic failure on postirradiation day 708. At necropsy, the irradiated right lobes of the liver were atrophic and the nonirradiated left lobes underwent compensatory hypertrophy. Hepatic arterioles and bile ducts were injured in every dog, but no obstructive lesions were observed in hepatic veins. Portal fibroplasia, bile retention, and proliferation of bile ductules was common; the latter two changes also occurred in the nonirradiated lobes. No qualitative differences were observed between hepatic lesions in neutron- versus photon-irradiated dogs. The relative biological effectiveness of fast neutrons for liver damage appears to be no less than 4.5.</p>","PeriodicalId":75672,"journal":{"name":"Cancer clinical trials","volume":"4 1","pages":"47-65"},"PeriodicalIF":0.0,"publicationDate":"1981-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"18228873","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Phase I--II evaluation of combination cyclophosphamide, 5-fluorouracil, hexamethylmelamine, and prednisone in advanced breast cancer. 环磷酰胺、5-氟尿嘧啶、六甲基三聚氰胺和强的松联合治疗晚期乳腺癌的I- II期评价
Cancer clinical trials Pub Date : 1981-01-01
Y C Chang, G Falkson, D C Tormey, J Crowley
{"title":"Phase I--II evaluation of combination cyclophosphamide, 5-fluorouracil, hexamethylmelamine, and prednisone in advanced breast cancer.","authors":"Y C Chang,&nbsp;G Falkson,&nbsp;D C Tormey,&nbsp;J Crowley","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>A four-drug combination of intermittent high-dose cyclophosphamide with 5-fluorouracil, hexamethylmelamine, and prednisone was given to 19 patients with advanced breast cancer. Objective response was documented in 7 of 18 evaluable patients. The median duration of response was 99 days. Response was observed in 6/7 patients without visceral disease and 1/11 patients with visceral disease. Toxicity was acceptable and no life-threatening toxicity was observed. Three patients have received the four-drug combination for more than 1 year without serious side effects. This regimen may serve as an alternative treatment for patients without visceral metastasis who have failed to respond to other combination chemotherapy regimens.</p>","PeriodicalId":75672,"journal":{"name":"Cancer clinical trials","volume":"4 4","pages":"377-80"},"PeriodicalIF":0.0,"publicationDate":"1981-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"17850576","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Phase II study of dibromodulcitol in colorectal, kidney, and other carcinomas. 二溴调质醇在结直肠癌、肾癌和其他癌症中的II期研究。
Cancer clinical trials Pub Date : 1981-01-01
N E Mischler, D C Tormey, J Klotz, E C Borden, G Ramirez, T K Banerjee, R M Carr, S D Zaentz, J Graf
{"title":"Phase II study of dibromodulcitol in colorectal, kidney, and other carcinomas.","authors":"N E Mischler,&nbsp;D C Tormey,&nbsp;J Klotz,&nbsp;E C Borden,&nbsp;G Ramirez,&nbsp;T K Banerjee,&nbsp;R M Carr,&nbsp;S D Zaentz,&nbsp;J Graf","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>In a phase II study dibromodulcitol (DBD), an alpha-omega dibrominated hexitol, was used to treat 99 previously treated patients with colon, rectal, kidney, and other tumors. Six patients were ineligible and 10 patients were nonevaluable for response. Aside from thrombocytopenia toxicity was moderate. Twenty-three patients had platelet nadirs of less than 50,000/mm3 and there were three thrombocytopenic-associated drug deaths. One of 21 rectal and 1 of 13 kidney cancer patients entered a remission. All but seven patients had received previous treatment with one or more cytotoxic agents. Previously treated patients with colorectal and kidney cancer appear to be resistant to DBD.</p>","PeriodicalId":75672,"journal":{"name":"Cancer clinical trials","volume":"4 4","pages":"407-10"},"PeriodicalIF":0.0,"publicationDate":"1981-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"18330104","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Phase II trial of methyl-G (methylglyoxal bis-guanylhydrazone) in patients with metastatic renal cell carcinoma. 甲基-g(甲基乙二醛双胍腙)在转移性肾细胞癌患者中的II期试验。
Cancer clinical trials Pub Date : 1981-01-01
J Z Fuks, D A Van Echo, J Aisner, E P Mitchell, P V Woolley, P H Wiernik
{"title":"Phase II trial of methyl-G (methylglyoxal bis-guanylhydrazone) in patients with metastatic renal cell carcinoma.","authors":"J Z Fuks,&nbsp;D A Van Echo,&nbsp;J Aisner,&nbsp;E P Mitchell,&nbsp;P V Woolley,&nbsp;P H Wiernik","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Fourteen patients with metastatic renal cell carcinoma received methyl-G weekly at a starting dose of 600 mg/m2 (five patients) and 500 mg/m2 (nine patients) intravenously. All 14 patients are evaluable for response and toxicity. No antitumor responses were observed. Six patients achieved stabilization of disease for 8 to 42 weeks. Toxicity was nonhematologic and included nausea or vomiting (35%), fever with shaking chills (28%), diarrhea (21%), myalgia (63%), paresthesia (49%), and bilateral foot drop (7%). Methyl-G does not appear to have activity against renal cell carcinoma.</p>","PeriodicalId":75672,"journal":{"name":"Cancer clinical trials","volume":"4 4","pages":"411-4"},"PeriodicalIF":0.0,"publicationDate":"1981-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"18330105","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
VP-16-213. A phase II trial using a weekly schedule. vp - 16 - 213。第二阶段试验采用每周计划。
Cancer clinical trials Pub Date : 1981-01-01
G Karp, K Antman, G Canellos
{"title":"VP-16-213. A phase II trial using a weekly schedule.","authors":"G Karp,&nbsp;K Antman,&nbsp;G Canellos","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Forty-six patients with various malignancies refractory to standard chemotherapy were treated with VP-16-213 using a weekly schedule. Only one patient responded to this regimen. perivenous infiltration of VP-16-213 resulted in a soft-tissue ulceration; this side effect has not been reported before. We conclude that VP-16-213 is of little utility when used in a weekly fashion in previously treated patients.</p>","PeriodicalId":75672,"journal":{"name":"Cancer clinical trials","volume":"4 4","pages":"465-7"},"PeriodicalIF":0.0,"publicationDate":"1981-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"18330111","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：604180095
Book学术官方微信
小红书